Fulcrum Therapeutics(FULC) - 2025 Q4 - Annual Results

Financial Position - Fulcrum Therapeutics reported cash, cash equivalents, and marketable securities of approximately $352.3 million as of December 31, 2025[6] - The cash figure is preliminary and unaudited, subject to completion of financial closing procedures[7] - Fulcrum's independent registered public accounting firm has not conducted an audit or review of the estimated cash figure[7] Corporate Events - Fulcrum plans to present business and strategic updates at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026[9] - A live webcast of the presentation will be available on Fulcrum's website[9] - The corporate presentation dated January 12, 2026, is attached as Exhibit 99.1 to the Current Report[11] - The report includes a corporate slide presentation reflecting business updates[9] Regulatory Compliance - Fulcrum is not classified as an emerging growth company under the Securities Act[5] - The company has not elected to use the extended transition period for complying with new financial accounting standards[5] - The report is intended to be furnished and not deemed "filed" under the Securities Exchange Act[8]